Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update
Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15,...
COVID-19
Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance
Expects Revenue for Full Year 2024 of $116 Million to $120 MillionBELGRADE, MT / ACCESSWIRE / May 15, 2024 /...
White House Highlights National Minority Quality Forum in Progress Report on Biden Cancer Moonshot
Washington, D.C.--(Newsfile Corp. - May 15, 2024) - The National Minority Quality Forum (NMQF), a non-profit health care research, education...
Zomedica Releases Over-the-Air Software Update Capabilities for Its TRUFORMA(R) Platform
OTA capability enhances introduction of new assays from rapidly expanding menuANN ARBOR, MI / ACCESSWIRE / May 15, 2024 /...
NanoViricides Has Filed its Quarterly Report
NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15,...
CLIAwaived, Inc. Named First Authorized Approved Distributor for Wondfo USA’s new WELLlife(TM) COVID-19/Influenza A&B POC and Home (OTC) Tests
CLIAwaived, Inc. has been named the first authorized approved distributor for Wondfo USA's innovative WELLlife™ COVID-19/Influenza A&B Point-of-Care (POC) and...
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Lecture to focus on engineering strategies applied to design safe and efficacious bispecific drug candidates, utilizing our proprietary platform technologiesSEATTLE,...
A Novel Broad-Spectrum Antiviral with Activity Against RSV
Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE /...
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an...
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
– Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training...
MiNK Reports First Quarter 2024 Results
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American...
Strawberry Fields REIT Announces First Quarter 2024 Operating Results
South Bend, Indiana--(Newsfile Corp. - May 14, 2024) - Strawberry Fields REIT, Inc. (NYSE American: STRW) (the "Company") reported today...
Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the...
Ainos Reports First Quarter 2024 Financial Results
Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024US$9M growth capital secured in May strengthens financial position for...
Moderna to Present at Upcoming Conferences in May/June 2024
CAMBRIDGE, MA / ACCESSWIRE / May 13, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming...
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a...
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the...
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand of approximately $110...